Table 1.
Characteristics of study population at first and at last visit
| Baseline | Last visit | |
|---|---|---|
| Age (years) | 39.4 ± 13.5 | 48.2 ± 14.2 |
| BMI (Kg/m2) | 24.6 ± 4.0 | 25.4 ± 4.3 |
| Waist circumference (cm) | 81.8 ± 11.4 | 87.4 ± 10.8 |
| SBP (mmHg) | 121.8 ± 15.7 | 119.1 ± 16.4 |
| DBP (mmHg) | 75.5 ± 10.2 | 73.6 ± 10.0 |
| MBP (mmHg) | 90.8 ± 11.2 | 88.6 ± 11.4 |
| PP (mmHg) | 46.4 ± 10.7 | 45.5 ± 10.6 |
| Fasting glucose (mg/dl) | 86.3 ± 16.3 | 95.2 ± 21.8 |
| Total cholesterol (mg/dl) | 207.4 ± 39.9 | 212.6 ± 41.6 |
| LDL cholesterol (mg/dl) | 126.0 ± 33.0 | 129.0 ± 35.6 |
| HDL cholesterol (mg/dl) | 64.9 ± 14.6 | 64.2 ± 14.5 |
| Triglycerides (mg/dl) | 80.8 ± 48.0 | 94.0 ± 52.3 |
| Serum creatinine (mg/dl) | 0.80 ± 0.19 | 0.85 ± 0.17 |
| Uric acid (mg/dl) | 4.0 ± 1.4 | 4.5 ± 1.4 |
| Diabetes mellitus (%) | 1.7 | 5.4 |
| Obesity (%) | 9.8 | 14.335.1 |
| Overweight (%) | 31.7 | |
| PWV (m/s) | 6.3 ± 1.9 | 7.3 ± 2.1 |
| PWV > 10 m/s (%) | 4.3 | 5.1 |
| Antihypertensive (%) | 4.5 | 10.6 |
| Antidiabetic (%) | 0.9 | 2.0 |
| Statins (%) | 1.2 | 6.5 |
| Antiplatelet drugs (%) | 0.8 | 4.9 |
| Insulin therapy (%) | 0.6 | 0.6 |
| Diuretics (%) | 1.8 | 3.6 |
| Beta-blockers (%) | 1.6 | 3.3 |
| Alpha-blockers (%) | 0.4 | 1.2 |
| CCB (%) | 1.0 | 1.5 |
| CEI and/or ATI blockers (%) | 2.5 | 4.3 |
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure, PP pulse pressure, LDL low-density lipoprotein, HDL high-density lipoprotein, PWV pulse-wave velocity, CCB calcium channel blocker, CEI converting enzyme inhibitor, ATI angiotensin type 1 receptor